posted on 2020-07-08, 14:40authored byFabian Hulpia, Gustavo D. Campagnaro, Khalid J. Alzahrani, Ibrahim A. Alfayez, Marzuq A. Ungogo, Dorien Mabille, Louis Maes, Harry P. de Koning, Guy Caljon, Serge Van Calenbergh
Human African trypanosomiasis is
a neglected tropical disease caused
by Trypanosoma brucei parasites. These
protists are unable to produce the purine ring, making them vulnerable
to the effects of purine nucleoside analogues. Starting from 3′-deoxytubercidin
(5), a lead compound with activity against central-nervous-stage
human African trypanosomiasis, we investigate the structure–activity
relationships of the purine and ribofuranose rings. The purine ring
tolerated only modifications at C7, while from the many alterations
of the 3′-deoxyribofuranosyl moiety only the arabino analogue 48 showed pronounced antitrypanosomal activity. Profiling
of the most potent analogues against resistant T. brucei strains (resistant to pentamidine, diminazene, and isometamidium)
showed reduced dependence on uptake mediated by the P2 aminopurine
transporter relative to 5. The introduction of a 7-substituent
confers up to 10-fold increased affinity for the P1 nucleoside transporter
while generally retaining high affinity for P2. Four of the most promising
analogues were found to be metabolically stable, earmarking them as
suitable backup analogues for lead 5.